The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

Grade 3 or higher AEs occurred in 34% of patients on the 4 mg dose and 56% on the 6 mg ... Tagrisso has repeatedly transformed expectations for patients with EGFR-mutated lung cancer by not only ...

Based on the criteria recently proposed by Ludwig et al, renal complete response (CRrenal) was defined as sustained (ie, at least 2 months') improvement of baseline GFR from < 50 mL/min to ≥ 60 ...

Image Source: Zacks Investment Research In August, the FDA approved Rybrevant in combination with oral EGFR-TKI inhibitor Lazcluze ... of 58 cents to earnings of 34 cents. Loss per share estimates ...

Overall, 56% and 34% of patients given the high and low doses ... approval of Datroway as a monotherapy in previously treated EGFR-mutated NSCLC. A decision from the agency is expected by July ...